Granted Patent
B2
US 12,297,232 · App. 17/187,214 · Granted May 13, 2025
Compositions and methods for mucosal vaccination against SARS-CoV-2
Inventors:
Xiaoping Zhu (Clarksville, MD); Weizhong Li (College Park, MD); Tao Wang (Ellicott City, MD)
Assignee:
University of Maryland, College Park
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-COV-2 antigen; and a trimerization domain. Disclosed are peptide complexes comprising three peptides, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-COV-2 antigen; and a trimerization domain. Disclosed are compositions comprising any of the disclosed peptides or peptide complexes. Disclosed are methods for eliciting a protective immune response against SARS-COV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein. Disclosed are methods of treating a subject exposed to SARS-COV-2 or at risk of being exposed to SARS-COV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein.
Claims (19)
1. A peptide comprising
a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn);
a full length soluble SARS-COV-2 spike(S) protein; and
a trimerization domain.
2. The peptide of claim 1 , wherein the monomeric Fc fragment of an immunoglobulin recognized by a FcRn comprises a mutation in the cysteine residues responsible for dimer formation.
3. The peptide of claim 2 , wherein the cysteine residues are at position 11 and 14 of SEQ ID NO:7.
4. The peptide of claim 2 , wherein the mutation is a cysteine to serine substitution.
5. The peptide of claim 1 , wherein C1q motif has been mutated such that it renders the fragment non-lytic.
6. The peptide of claim 1 , wherein the monomeric Fc fragment of an immunoglobulin recognized by a FcRn comprises a CH2 domain and a CH3 domain.
7. The peptide of claim 6 , wherein the monomeric Fc fragment of an immunoglobulin recognized by a FcRn comprises one or more mutations in the CH2 domain, wherein the one or more mutations in the CH2 domain ablate C1q binding to the monomeric Fc fragment.
8. The peptide of claim 1 , wherein the trimerization domain is a T4 fibritin trimerization domain.
9. The peptide of claim 1 , wherein the monomeric Fc fragment is conjugated to the carboxy terminal end of the full length soluble SARS-COV-2 spike protein.
10. A peptide complex comprising three peptides, wherein each of the peptides is the peptide of claim 1 .
11. A composition comprising the peptide of claim 1 .
12. A composition comprising the peptide complex of claim 10 .
13. A method for eliciting a protective immune response against SARS-COV-2 comprising administering to a subject an effective amount of the composition of claim 11 .
14. A method for eliciting a protective immune response against SARS-COV-2 comprising administering to a subject an effective amount of a composition comprising a peptide complex, wherein the peptide complex comprises three peptides forming a trimer, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; a full length soluble SARS-COV-2 S protein; and a trimerization domain, wherein the administering is to a mucosal epithelium.
15. A method of treating a subject exposed to SARS-COV-2 or at risk of being exposed to SARS-COV-2 comprising administering to the subject an effective amount of the composition of claim 11 .
16. A method of treating a subject exposed to SARS-COV-2 or at risk of being exposed to SARS-COV-2 comprising administering to the subject an effective amount of a composition comprising a peptide complex, wherein the peptide complex comprises three peptides forming a trimer, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; a full length soluble SARS-COV-2 S protein; and a trimerization domain, wherein the administering is to a mucosal epithelium.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 5, 2025
From: ZHU, XIAOPING; LI, WEIZHONG; WANG, TAO
To: UNIVERSITY OF MARYLAND, COLLEGE PARK
Reel/Frame 072786/0083 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 13, 2022
From: ZHU, XIAOPING; LI, WEIZHONG; WANG, TAO
To: UNIVERSITY OF MARYLAND, COLLEGE PARK
Reel/Frame 061077/0283 →
Continuity (2)
Provisional Application
62981873
· Feb 26, 2020
References Cited (165)
US 20070009523A1
· Presta
· 2007
[cited by examiner]
US 20150125473A1
· Burt et al.
· 2015
[cited by applicant]
WO WO2019046864A1
· 2019
[cited by applicant]
WO WO2019046859A1
· 2019
[cited by examiner]
Wrapp et al, Science 367, 1260-1263 (2020). (Year: 2020).
[cited by examiner]
Written Opinion and Search Report issued Jul. 1, 2021 by the International Search Report for Application No. PCT/US2021/020099 filed on Feb. 26, 2021 (Applicant: University of Maryland) (10 pages).
[cited by applicant]
Walls et al. “Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein” bioRxiv, Feb. 20, 2020; Cell 180, 281-292, Apr. 16, 2020.
[cited by applicant]
U.S. Appl. No. 62/981,873, filed Feb. 26, 2020, Xiaoping Zhu (University of Maryland).
[cited by applicant]
PCT, PCT/US2012/020099 (WO/2021174128), Feb. 26, 2021, (Sep. 2, 2021), Xiaoping Zhu (University of Maryland).
[cited by applicant]
U.S. Appl. No. 18/517,578, filed Nov. 22, 2023, Zhu.
[cited by applicant]
U.S. Appl. No. 16/373,272, filed Apr. 2, 2019, Zhu.
[cited by applicant]
U.S. Appl. No. 17/831,928, filed Jun. 3, 2022, Zhu.
[cited by applicant]
Allie SR, Randall TD. Pulmonary immunity to viruses. Clin Sci (Lond). Jun. 30, 2017;131(14):1737-1762.
[cited by applicant]
Bai Y, et al.(2011) Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Proc Natl Acad Sci U S A. 108:18406-11.
[cited by applicant]
Barría MI, et al (2013) Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis. 207:115-24.
[cited by applicant]
Berneman A, Belec L, Fischetti VA, Bouvet JP. 1998. The specificity patterns of human immunoglobulin G antibodies in serum differ from those in autologous secretions. Infect Immun. 66:4163-4168.
[cited by applicant]
Boukhvalova MS, Blanco JC. 2013. The cotton rat Sigmodon hispidus model of respiratory syncytial virus infection. Curr Top Microbiol Immunol. 372:347-58.
[cited by applicant]
Brokstad KA (2002) Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis. 185:878-84.
[cited by applicant]
Brown DM, et al. (2012) Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol. 86:6792-803.
[cited by applicant]
Castilow EM, Varga SM. 2008. Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol. 3:445-454.
[cited by applicant]
Chiu C, Openshaw PJ (2015) Antiviral B cell and T cell immunity in the lungs. Nat Immunol. 16:18-26.
[cited by applicant]
Cullen LM, Blanco JC, Morrison TG. 2015. Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. J Transl Med. 13:350.
[cited by applicant]
Dickinson BL, et al. (1999) Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest. 104:903-11.
[cited by applicant]
Duncan AR, Winter G (1988) The binding site for C1q on IgG. Nature. 332:738-40.
[cited by applicant]
Ekiert DC, et al. (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 333:843-50.
[cited by applicant]
Erbelding EJ, et al. (2018) A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis. 218:347-54.
[cited by applicant]
Ermler ME, et al. (2017) Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model. J Virol. 91: pii: e00286-17.
[cited by applicant]
Frey A, Di Canzio J, Zurakowski D (1998) A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods, 221:35-41.
[cited by applicant]
Friesen RH, et al. (2014) A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A. Jan. 7, 2014;111(1):445-50.
[cited by applicant]
Garg R, Latimer L, Simko E, Gerdts V, Potter A, van den Hurk Sv. Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation. J Gen Virol. Feb. …
[cited by applicant]
Garg R, Theaker M, Martinez EC, van Drunen Littel-van den Hurk S. A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus. Virology…
[cited by applicant]
Gebril A, Alsaadi M, Acevedo R, Mullen AB, Ferro VA. 2012. Optimizing efficacy of mucosal vaccines. Expert Rev Vaccines. 11:1139-55.
[cited by applicant]
Graham BS, Modjarrad K, Mclellan JS. 2015. Novel antigens for RSV vaccines. Curr Opin Immunol. 35:30-8.
[cited by applicant]
Hirst GK (1942) The Quantitative Determination of Influenza Virus and Abs by Means of Red Cell Agglutination. J. Exp. Med. 75:49-64.
[cited by applicant]
Hodge LM, et al. (2001) Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization. Infect Immun. 69:2328-38.
[cited by applicant]
Holmgren J, Svennerholm AM. 2012. Vaccines against mucosal infections. Curr Opin Immunol. 24:343-53.
[cited by applicant]
Houser K, Subbarao K (2015) Influenza vaccines: challenges and solutions. Cell Host Microbe. 17:295-300.
[cited by applicant]
Iho S, Maeyama J, Suzuki F (2015) CpG oligodeoxynucleotides as mucosal adjuvants. Hum Vaccin Immunother. 11:755-60.
[cited by applicant]
Iijima N, Iwasaki A (2015) Tissue instruction for migration and retention of TRM cells. Trends Immunol. 36:556-64.
[cited by applicant]
Iwasaki A. (2016) Exploiting Mucosal Immunity for Antiviral Vaccines. Annu Rev Immunol. 34:575-608.
[cited by applicant]
Iwasaki A, Foxman EF, Molony RD (2017) Early local immune defenses in the respiratory tract. Nat Rev Immunol. 17:7-20.
[cited by applicant]
Johnson TR, Rangel D, Graham BS, Brough DE, Gall JG. Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol Ther. Jan. 2014;22(1):196-205.
[cited by applicant]
Johnson TR, Rao S, Seder RA, Chen M, Graham BS. 2009. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection…
[cited by applicant]
Joyce MG, et al. 2016. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol. 23:811-20.
[cited by applicant]
Kim JK, Tsen MF, Ghetie V, Ward ES (1994) Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur J Immunol. 24:2429-34.
[cited by applicant]
Kinnear E, Lambert L, McDonald JU, Cheeseman HM, Caproni LJ, Tregoning JS. Airway T cells protect against RSV infection in the absence of antibody. Mucosal Immunol. May 24, 2017.
[cited by applicant]
Ko SY, et al. (2014) Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 514:642-5.
[cited by applicant]
Krammer F, et al. (2012) A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One. 7:e43603.
[cited by applicant]
Krammer F, Pica N, Hai R, Margine I, Palese P (2013) Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific Abs. J Virol. 87:6542-50.
[cited by applicant]
Krammer F, et al. (2014) Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol. 88:3432-42.
[cited by applicant]
Krammer F, Palese P. (2015) Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 14:167-82.
[cited by applicant]
Krarup A, et al., 2015. A highly stable prefusion Rsv F vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 6:8143.
[cited by applicant]
Laidlaw BJ, et al. (2014) CD4+ T cell help guides formation of CD103+ lung-resident memory CD8+ T cells during influenza viral infection. Immunity. 41:633-45.
[cited by applicant]
Liang et al., Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate. J Virol. 2015, vol. 89(18), p. 9499-510.
[cited by applicant]
Lu et al. A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol. Oct. 2011. pp. 10542-10553, vol. 85, No. 20.
[cited by applicant]
McGhee JR. 2011. A mucosal gateway for vaccines. Nat Biotechnol. 29:136-8.
[cited by applicant]
McLellan et al., Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus. Science. 2013, vol. 342(6158), pp. 592-598.
[cited by applicant]
McMaster SR, Wilson JJ, Wang H, Kohlmeier JE (2015) Airway-Resident Memory CD8 T Cells Provide Antigen-Specific Protection against Respiratory Virus Challenge through Rapid IFN-γ Production. J Immunol. 195:203-9.
[cited by applicant]
McMaster SR, et al. (2018) Pulmonary antigen encounter regulates the establishment of tissue-resident CD8 memory T cells in the lung airways and parenchyma. Mucosal Immunol. 11:1071-8.
[cited by applicant]
Major D, et al. (2015) Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge. Hum Vaccin Immunother. 11:1235-43.
[cited by applicant]
Margine I, et al. (2013) Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol. 87:10435-46.
[cited by applicant]
Minne A, et al. (2007) The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology. 122:316-25.
[cited by applicant]
Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, Openshaw PJ. 2006. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med. 12:905-7.
[cited by applicant]
Morabito KM, Ruckwardt TR, Redwood AJ, Moin SM, Price DA, Graham BS. 2017. Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. M…
[cited by applicant]
Mueller SN, Gebhardt T, Carbone FR, Heath WR (2013) Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol. 31:137-61.
[cited by applicant]
Muszkat M, et al. (2003) Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine. 21:1180-6.
[cited by applicant]
Neutra MR, Kozlowski PA. 2006. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 6:148-58.
[cited by applicant]
Ngwuta JO, et al. 2015. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med. 7:309ra162.
[cited by applicant]
Oh S, et al. (2009) Neutralizing monoclonal Abs to different clades of Influenza A H5N1 viruses. J Virol Methods. 157:161-7.
[cited by applicant]
Openshaw PJ, Tregoning JS. 2005. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev. 18:541-55.
[cited by applicant]
Oshansky CM, Zhang W, Moore E, Tripp RA. 2009. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol. 4:279-97.
[cited by applicant]
Palomo C, et al. 2016. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses. J Virol. 90:5485-98.
[cited by applicant]
Passmore C, et al. Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model. Hum Vaccin Immunother. 2014;10(3):615-22.
[cited by applicant]
Pavot V, Rochereau N, Genin C, Verrier B, Paul S. 2012. New insights in mucosal vaccine development. Vaccine. 30:142-54.
[cited by applicant]
Pierantoni A, et al. Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates. Mol Ther Methods Clin Dev. May 20, 2015;2:15018.
[cited by applicant]
Pizzolla A, et al. (2017) Resident memory CD8+T cells in the upper respiratory tract prevent pulmonary influenza virus infection. Sci Immunol. 2. pii: eaam6970.
[cited by applicant]
Qiao SW, et al. (2008) Dependence of Ab mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A. 105:9337-42.
[cited by applicant]
Rath et al., Regulation of immune responses by the neonatal Fc receptor and its therapeutic implications. Front Immunol. 2015, vol. 5:664.
[cited by applicant]
Renegar KB, Small PA Jr, Boykins LG, Wright PF (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol. 173:1978-86.
[cited by applicant]
Ruan et al., Suppressive effect of locally produced interleukin-10 on respiratory syncytial virus infection. Immunology. 2001, vol. 104(3), p. 355-60.
[cited by applicant]
Sallusto F, Lanzavecchia A, Araki K, Ahmed R (2010) From vaccines to memory and back. Immunity. 33:451-63.
[cited by applicant]
Slifka MK, Antia R, Whitmire JK, Ahmed R (1998) Humoral immunity due to long-lived plasma cells. Immunity. 8:363-72.
[cited by applicant]
Slütter B, et al. (2017) Dynamics of influenza-induced lung-resident memory T cells underlie waning heterosubtypic immunity. Sci Immunol. 2. pii: eaag2031.
[cited by applicant]
Spiekermann GM, et al. (2002) Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med. 196:303-10.
[cited by applicant]
Tan GS, et al. (2012) A pan-H1 anti-hemagglutinin monoclonal Ab with potent broad-spectrum efficacy in vivo. J Virol. 86:6179-88.
[cited by applicant]
Turner DL, Farber DL (2014) Mucosal resident memory CD4 T cells in protection and immunopathology. Front Immunol. 14;5:331.
[cited by applicant]
Van Riet E, Ainai A, Suzuki T, Hasegawa H (2012) Mucosal IgA responses in influenza virus infections; thoughts for vaccine design. Vaccine. 30:5893-900.
[cited by applicant]
Vaughn DE, Bjorkman PJ. (1998) Structural basis of pH-dependent Ab binding by the neonatal Fc receptor. Structure. 6:63-73.
[cited by applicant]
Vissers M, Ahout IML, de Jonge MI, Ferwerda G. 2016. Mucosal IgG levels correlate better with respiratory syncytial virus load and inflammation than plasma IgG levels. Clin Vaccine Immunol 23:243-245.
[cited by applicant]
Weldon WC, et al. (2010) Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One. 5. pii: e12466.
[cited by applicant]
Wu T, et al. (2014) Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. J Leukoc Biol. 95:215-24.
[cited by applicant]
Yang K, Varga SM. 2014. Mucosal vaccines against respiratory syncytial virus. Curr Opin Virol. 6:78-84.
[cited by applicant]
Yoshida M, et al. (2006) Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest. 116:2142-2151.
[cited by applicant]
Zens KD, Chen JK, Farber DL (2016) Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight. 1. pii: e85832.
[cited by applicant]
Zhirnov OP, Ikizler MR, Wright PF (2002) Cleavage of influenza a virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases. J Virol. 76:8682-9.
[cited by applicant]
International Search Report and Written Opinion were mailed on Feb. 22, 2019 by the International Searching Authority for International Application No. PCT/US2018/055896, filed on Oct. 15, 2018 and published as WO 2019/…
[cited by applicant]
Afkhami, S. et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
[cited by applicant]
Al-Aly Z, Bowe B, & Xie Y. Long COVID after breakthrough SARS-CoV-2 infection.
[cited by applicant]
Allie, S. R et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat. Immunol. 20, 97-108 (2019).
[cited by applicant]
Andrews, M. G. et al. Tropism of SARS-CoV-2 for human cortical astrocytes.
[cited by applicant]
Baker, K. et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells.
[cited by applicant]
Bauer, L. et al. The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2.
[cited by applicant]
Chandrashekar, A. et al. Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.
[cited by applicant]
Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
[cited by applicant]
Dekkers, G. et al. Affinity of human IgG subclasses to mouse Fc gamma receptors.
[cited by applicant]
Du, L. et al. The spike protein of SARS-CoV—a target for vaccine and therapeutic development.
[cited by applicant]
Fischer, H. & Widdicombe, J. H. Mechanisms of acid and base secretion by the airway epithelium.
[cited by applicant]
Fröberg, J et al. SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms.
[cited by applicant]
Golden, J. W. et al. Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2.
[cited by applicant]
Grau-Expósito, J. et al. Peripheral and lung resident memory T cell responses against SARS-CoV-2.
[cited by applicant]
Hassan, A. O. et al. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.
[cited by applicant]
Hartwell, B. L. et al. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity.
[cited by applicant]
He, W. et al. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography.
[cited by applicant]
Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract.
[cited by applicant]
Hunter, P. Viral diseases and the brain: Long COVID puts the spotlight on how viral infections affect the brain.
[cited by applicant]
Idusogie, E, E, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human lgG1 Fc.
[cited by applicant]
Jeyanathan, M. et al. Immunological considerations for COVID-19 vaccine strategies.
[cited by applicant]
Kubo, T. et al. CpG-DNA enhances the tight junction integrity of the bronchial epithelial cell barrier.
[cited by applicant]
Letarov, A.V., Londer, et al., The carboxy-terminal domain initiates trimerization of bacteriophage T4 fibritin.
[cited by applicant]
Li, Z. et al. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection.
[cited by applicant]
Liu, X. et al. The neonatal FcR-mediated presentation of immune-complexed antigen is associated with endosomal and phagosomal pH and antigen stability in macrophages and dendritic cells.
[cited by applicant]
Lu, L. et al. A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection.
[cited by applicant]
Lipsitch, M., Krammer, F., Regev-Yochay, G., Lustig, Y., & Balicer, R.D. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact.
[cited by applicant]
Lund, F. E. & Randall, T. D. Scent of a vaccine.
[cited by applicant]
Mao, T. et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 378(872), pp. 1-14, eabo2523 (2022).
[cited by applicant]
Meinhardt, J. et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19.
[cited by applicant]
Ochsner, S. P. et al. FcRn-Targeted Mucosal Vaccination against Influenza Virus Infection.
[cited by applicant]
Oh, J. E. et al. Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA.
[cited by applicant]
Oladunni, F. S. et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice.
[cited by applicant]
Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.
[cited by applicant]
Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
[cited by applicant]
Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age.
[cited by applicant]
Roukens, A. H. E. et al. Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8
[cited by applicant]
Russell, M. W. & Mestecky, J. Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission.
[cited by applicant]
Sakurai, A. et al. Natural History of Asymptomatic SARS-CoV-2 Infection.
[cited by applicant]
Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters.
[cited by applicant]
Spiekermann, G. M. et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung.
[cited by applicant]
Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2.
[cited by applicant]
Sui, Y. et al. Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCI Insight. Apr. 28, 2021;6(10): e148494.
[cited by applicant]
Szabo, P. A., Miron, M., & Farber, D. L. Location, location, location: Tissue resident memory T cells in mice and humans. Sci. Immunol. 4(34), eaas9673 (2019).
[cited by applicant]
Tang, J. et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination.
[cited by applicant]
Van Doremalen, N. et al. ChAdOx1 nCOV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.
[cited by applicant]
V'kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2.
[cited by applicant]
Walls A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
[cited by applicant]
Ward, E.S., Zhou, J., Ghetie, V., & Ober, R. J. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans.
[cited by applicant]
Ye, L., Zeng, R., Bai, Y., Roopenian, D. C., & Zhu, X. Efficient mucosal vaccination mediated by the neonatal Fc receptor.
[cited by applicant]
Yen, H. L. et al. Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study.
[cited by applicant]
Yoshida, M. et al. Human neonatal Fc receptor mediates transport of IG into luminal secretions for delivery of antigens to mucosal dendritic cells.
[cited by applicant]
Zeng, et al. SARS-CoV-2 spreads through cell-to-cell transmission.
[cited by applicant]
Zhou, D. et al. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies.
[cited by applicant]
An, Xingyue et al., “Single-does intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2,” BioRxiv, XP093120206, DOI: 10.1101/2020.07.23.212357 (2020).
[cited by applicant]
Li, Jie et al., “Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates,” Viral Immunology, 26(2): 126-132 (2013).
[cited by applicant]
Li, Weizhong et al., An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission, bioRxiv, XP093119729, DOI: 10.1101/2022.11.23.517678 (2022).
[cited by applicant]
Shan et al., Communications Biology (2021) 4:1048; and https://doi.org/10.1038/s42003-021-02566-5, Nature.com/commsbio (Year: 2021).
[cited by applicant]
Supplementary European Search Report mailed Jan. 29, 2024 for EP 21760268.9, filed Sep. 23, 2022.
[cited by applicant]